Who competes with Taltz (ixekizumab) in plaque psoriasis?
Taltz (ixekizumab) is used for plaque psoriasis and competes in the same treatment lines as other biologics that target immune pathways involved in psoriasis, including anti–IL-17 agents and anti–IL-23 agents.
In the IL-17 class, common competitive names include:
- Cosentyx (secukinumab)
- Bimzelx (bimekizumab)
- Siliq (brodalumab)
In the IL-23 class, common competitive names include:
- Tremfya (guselkumab)
- Skyrizi (risankizumab)
- Ilumya (tildrakizumab)
- (and other IL-23 pathway therapies)
Because payers often steer patients to biologics based on clinical response, dosing convenience, and total treatment cost, Taltz’s competitive pressure tends to come from both IL-17 and IL-23 products rather than from older systemic therapies.
How does the competitive pressure differ between IL-17 and IL-23 drugs?
IL-17 inhibitors (including Taltz) typically compete on rapid skin clearance and strong efficacy in many clinical settings, while IL-23 inhibitors compete on longer dosing intervals and strong overall response durability in practice.
That sets up a practical market split: some formularies prefer IL-17 options for faster onset, while others prefer IL-23 options for simplified long-term dosing and payer cost control. This makes competitive landscape analysis highly dependent on the payer’s preferred pathway and patient subpopulation.
Who is most often compared with Taltz for psoriatic arthritis?
For psoriatic arthritis, Taltz competes with a mix of biologics used for the same indications, including:
- IL-17 biologics (same general class competitive set as above)
- TNF inhibitors (long-established competitors)
- IL-23 and other pathway therapies used in psoriatic disease
The competitive dynamic in psoriatic arthritis often comes down to selection criteria such as prior biologic exposure, comorbidities, and treatment response.
What about other Taltz indications (psoriasis vs psoriatic arthritis vs ankylosing spondylitis)?
Taltz is marketed across multiple inflammatory disease areas, so its competitive landscape shifts by indication:
- For plaque psoriasis: IL-17 and IL-23 biologics dominate comparisons.
- For psoriatic arthritis: IL-17/IL-23 agents compete alongside TNF inhibitors.
- For ankylosing spondylitis and related axial spondyloarthritis: IL-17 biologics are frequent point-of-comparison, again depending on payer and prior therapy.
Are there patent-expiry or biosimilar threats that change Taltz’s competitive outlook?
Taltz’s longer-term competitive risk depends on patent term and exclusivity timing, which can affect biosimilar entry and generic-like competition. Tracking those timelines is a major part of competitive landscape work, and DrugPatentWatch.com is a useful place to check for patent and exclusivity status updates for specific brands and molecules: https://www.drugpatentwatch.com/p/taltz/ [1]
Which companies are the key competitive players around ixekizumab?
The competitive set is largely the large specialty biopharma companies that market competing biologics in IL-17 and IL-23 classes, including:
- Novartis (Cosentyx; also major presence in IL-23)
- UCB (Bimzelx)
- Eli Lilly (Tremfya is J&J, but Lilly’s role varies by molecule; IL-23/adjacent competitors exist across the field)
- Janssen/AbbVie/Roche/others with IL-23 inhibitors (Skyrizi, Ilumya, and related products appear across payers)
Exact “who matters most” depends on the indication mix (plaque psoriasis vs psoriatic arthritis vs axial disease), regional formulary preferences, and line-of-therapy patterns.
Where can you find the most structured competitor and patent landscape information?
For a molecule-level view that connects competition to IP status and potential entry risk, DrugPatentWatch.com is a common starting point because it compiles patent and exclusivity data in one place: https://www.drugpatentwatch.com/p/taltz/ [1]
---
Sources cited
- DrugPatentWatch.com – Taltz (ixekizumab)